References
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008;359(4):378-390.
- Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness. Am J Gastroenterol 2008; 103(4):914-921.
- Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu R, Antiangiogenic Therapy Enhances the Efficacy of Transcatheter Arterial Embolization for Hepatocellular Carcinomas. Int J Cancer 2007;121(2):416-424.
- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 Easl Conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430.
- Bruix J and Sherman M. Management of Hepatocellular Carcinoma. Hepatology 2005;42(5):1208-1236.
- Reyes D, Azad N, Kamel I, Koteish A, Hamilton J, Pawlik T, Phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization (DEB-TACE) for patients with hepatocellular carcinoma (HCC): interim safety and efficacy analysis. Hepatology 2009;50(6):6A.
- Erhardt A, Kolligs F, Dollinger M, Schott E, Lohse A, Bitzer M, First-in men demonstration of sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma (Socrates trial). Hepatology 2009;50(4)Suppl: 1080A.
- Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Randomized Controlled Trial of Transarterial Lipiodol Chemoembolization for Unresectable Hepatocellular Carcinoma. Hepatology 2002;35(5):1164-1171.
- Semela D and Dufour JF. Angiogenesis and Hepatocellular Carcinoma. J Hepatol 2004;41(5):864-880.
- Trotti A, Colevas D, Setser A, Rusch V, Jaques D, Budach V, CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13(3):176-181.